The ability of p32 CAR T cells to recognize and eliminate glioma cells in different phenotypic/differentiated states provides an advantage to this strategy over the existing conventional therapies and the possibility of combining these therapeutic approaches for the treatment of GBM. This evidence concerns the gene C1QBP and glioma.